Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Qingzhen Oral Liquid is an investigational Traditional Chinese Medicine (TCM) developed by Shandong Kangzhonghong Pharmaceutical Technology Development Co., Ltd. specifically for the treatment of hand, foot, and mouth disease (HFMD) in pediatric patients. The formulation is designed to clear heat, detoxify, and cool the blood, addressing the clinical manifestations of HFMD such as fever, skin rashes, and oral ulcers. It is administered as an oral solution and is composed of several herbal extracts known for their antiviral and anti-inflammatory properties. Clinical evaluation in China, including Phase II trials, has focused on its efficacy in reducing the duration of symptoms and preventing the progression of the disease caused by enteroviruses such as Enterovirus 71 (EV71) and Coxsackievirus A16 (CV-A16).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Qingzhen Oral Liquid.